Cancer Drug Articles & Analysis
47 articles found
Population growth, aging populations and increases in cancer incidence have necessitated new approaches to identifying effective treatments. One such approach involves the repositioning, or repurposing, of drugs already FDA approved in either non-oncology disease states and/or approved in a limited number of tumor types. ...
Whether it is medical research or drug manufacturing, tablet press is a vital link. Let's see how to choose the one that suits you best.Grand pack.The field of drug delivery is constantly evolving, driven by the core goal of improving therapeutic outcomes—enhancing efficacy, reducing toxicity, boosting patient compliance, and even enabling entirely new medical treatments. The global drug delivery ...
Challenges and Current Research Directions Despite significant progress, several research challenges in BCL2 biology remain. One of the key issues is drug resistance. Cancer cells often develop resistance to BCL2 inhibitors by upregulating other anti-apoptotic proteins like MCL1 or BCL-XL. ...
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug ...
Therefore, comprehensive drug development is pivotal in addressing these challenges and enhancing therapeutic outcomes in brain cancer treatment. ...
Cancer is a worldwide disease and one of the leading causes of morbidity and mortality today. ...
By introducing a functional gene into the cells with these symptoms, researchers hope to correct the inherited gene mutation and potentially cure the disease. Gene delivery in cancer treatment involves the use of viral or non-viral vectors to deliver therapeutic genes into cancer cells. These approaches allow the targeted delivery of genes that can inhibit ...
Disease MechanismsStudy changes in oxidative phosphorylation in various diseases (such as neurodegenerative diseases, cancer).3. Drug Screening and Toxicity TestingEvaluate the impact of drugs on mitochondrial function.Precautions1. ...
Alfa Cytology has announced pancreatic cancer vaccine development services to improve the efficacy and safety of related vaccines. Alfa Cytology, a biotech company composed of scientists, bioinformatics, and oncologists, has recently announced its pancreatic cancer vaccine development services to provide further strategies for cancer therapy ...
Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. ...
Alfa Cytology has announced tumor models customization service for pancreatic cancer research. Alfa Cytology, a biotech company specializing in cancer research, has recently unveiled the service on pancreatic cancer tumor model customization to dig into the generation and development of pancreatic cancer and correspondingly ...
They are essential in unraveling the molecular mechanisms underlying cell death and are instrumental in drug development, cancer research, and developmental biology. Types of Apoptosis Assays Morphological Assays: These assays examine the characteristic morphological changes that occur during apoptosis. ...
To begin with, SN38-BSA is composed of SN38, a potent anti-cancer drug, and BSA or Bovine Serum Albumin. SN38 is the active metabolite of the prodrug irinotecan, commonly used in chemotherapy. ...
The classical mode of action of small molecule drugs is "occupancy-driven". Since the FDA approved the first oral small molecule targeted therapy for tumors-tamoxifen targeting the estrogen receptor (ER)-in 1977 for the treatment of breast cancer, small molecule drug development has typically focused on screening for high-affinity inhibitors. ...
This conjugate can selectively deliver the drug to disease-related cells, such as cancer cells, thereby increasing efficacy and reducing toxicity to normal tissues.ADC is a complex composed of an antibody and a drug (usually a cytotoxic drug). The antibody component specifically targets surface antigens on specific ...
Car-t cell therapy involves genetically engineering T cells isolated from patients or allogeneic donors to express chimeric antigen receptors (CAR) that specifically recognize and kill tumor cells. As a "living" drug, CAR-T therapy is very different from traditional drugs. It is a new type of precision targeted therapy for the treatment of tumors. ...
Repurposing Existing Drugs: By analyzing drug-disease relationships, scientists can discover new therapeutic applications for existing drugs. ...
Two are for HER2 breast cancer ADCs. T-DM1(Ado-trastuzumab Emtansine) T-DM1 is the first ADC drug to target HER2-positive breast cancer. ...
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. ...
The company has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for immune and cancer research. As immunotherapy gains widespread use, increasing attention is being focused on T-cell clone diversity and clonality, which is crucial for evaluating the effectiveness ...